Article
Oncology
Sanjal Desai, Muhamad Alhaj Moustafa, Gregory Wiseman, Thomas Witzig
Summary: Primary gastrointestinal follicular lymphoma (PGIFL) is characterized by localized involvement of the gastrointestinal tract. External beam radiation therapy is curative for many localized follicular lymphomas, but its use in PGIFL may be hindered by gastrointestinal toxicities. Ibritumomab tiuxetan radioimmunotherapy (RIT) delivers high-intensity radiation specifically targeting lymphoma cells with tolerable toxicity, making it a potentially curative treatment option for PGIFL.
Article
Oncology
Muhamad Alhaj Moustafa, Jennifer Peterson, Bradford S. Hoppe, Jennifer Jiang, Gregory A. Wiseman, Thomas E. Witzig, Han W. Tun
Summary: In a cohort of previously untreated LG-FL or MZL patients, (90)Y-IT treatment achieved an overall response rate of 100% and a complete response rate of 94%. Long-term complete response was observed in 25% of patients. Bulky disease was associated with a shorter median progression-free survival compared to non-bulky disease. The incidence of grade 3 or higher thrombocytopenia, neutropenia, and anemia were 47%, 37%, and 4%, respectively. No therapy-related myelodysplasia or acute myeloid leukemia were observed.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Oncology
Katsuhiro Miura, Hideki Tsujimura, Yasufumi Masaki, Masaki Iino, Jun Takizawa, Yoshinobu Maeda, Kazuhiko Yamamoto, Shinobu Tamura, Akiyo Yoshida, Hideo Yagi, Isao Yoshida, Koichi Kitazume, Taro Masunari, Ilseung Choi, Yasutaka Kakinoki, Ritsuro Suzuki, Tadashi Yoshino, Shigeo Nakamura, Yoshihiro Hatta, Takashi Yoshida, Masatoshi Kanno
Summary: The study evaluated the efficacy and safety of consolidation therapy with Y-90-IT after re-induction therapy with BR in patients with previously treated FL. Among the 22 patients who received Y-90-IT consolidation, the 2-year PFS rate was 59%, and patients whose remission lasted ≥2 years had a significantly higher PFS rate. Major adverse events were hematological toxicities, but acceptable, and the estimated 2-year overall survival after consolidation was 95%.
HEMATOLOGICAL ONCOLOGY
(2021)
Article
Hematology
Ilseung Choi, Masaya Okada, Tomoki Ito
Summary: Yttrium-90 ibritumomab tiuxetan (90YIT) is a radioimmunotherapy agent used for relapsed or refractory low-grade B-cell non-Hodgkin's lymphoma (rr-B-NHL). A joint study evaluated the clinical outcome of 90YIT, analyzing data from 316 patients. The median PFS was 3.0 years, the final OS rate was over 60%, and significant factors influencing PFS and OS were identified. The study found that prognosis following 90YIT treatment improved in the later half era compared to the earlier half era.
ANNALS OF HEMATOLOGY
(2023)
Article
Hematology
Kathrin Rieger, Rosaria De Filippi, Ola Linden, Andreas Viardot, Georg Hess, Kristina Lerch, Peter Neumeister, Andrea Stroux, Caroline A. Peuker, Antonio Pezzutto, Antonello Pinto, Ulrich Keller, Christian W. Scholz
Summary: Radioimmunotherapy with 90Y-IT as first-line treatment in patients with follicular lymphoma demonstrated long-term clinical activity and favorable safety profile, with a median progression-free survival of 3.6 years and an 8-year overall survival of 69.2%.
ANNALS OF HEMATOLOGY
(2022)
Article
Oncology
Richard L. Wahl, Eric C. Frey, Heather A. Jacene, Brad S. Kahl, Steven Piantadosi, Jesus A. Bianco, Richard J. Hammes, Miah Jung, Wayne Kasecamp, Bin He, George Sgouros, Ian W. Flinn, Lode J. Swinnen
Summary: The study evaluates the feasibility of SPECT-CT/planar organ dosimetry-based radiation dose escalation radioimmunotherapy in patients with recurrent non-Hodgkin's lymphoma. The approach was patient-specific and showed efficient tumor response rates, variability in liver dosimetry, and feasibility of exceeding FDA-approved activity. The study supports the feasibility of patient-specific dose escalation in the treatment of NHL with stem cell transplant.
Article
Oncology
Felipe Samaniego, Peter McLaughlin, Sattva S. Neelapu, Lei Feng, Michelle Fanale, Loretta Nastoupil, Maria Alma Rodriguez, Barbara Pro, Erin Taylor, Fredrick B. Hagemeister, Nathan Fowler
Summary: The sequential treatment approach of R-FND followed by(90)YIT consolidation and rituximab maintenance showed favorable outcomes in high-risk follicular lymphoma patients, with a 10-year progression-free survival rate of 49%.
LEUKEMIA & LYMPHOMA
(2021)
Article
Multidisciplinary Sciences
Mario Bunse, Janina Pfeilschifter, Julia Bluhm, Maria Zschummel, Jara J. Joedicke, Anthea Wirges, Helen Stark, Vivien Kretschmer, Markus Chmielewski, Wolfgang Uckert, Hinrich Abken, Joerg Westermann, Armin Rehm, Uta E. Hoepken
Summary: The study demonstrates that CAR-T cells targeting CXCR5 effectively inhibit tumor growth by depleting both B cells and follicular T helper cells in lymphoma models, suggesting a promising treatment strategy for nodal B-NHLs.
NATURE COMMUNICATIONS
(2021)
Review
Radiology, Nuclear Medicine & Medical Imaging
Francesco Cicone, Anna Sarnelli, Claretta Guidi, Maria Luisa Belli, Mahila Esmeralda Ferrari, Richard Wahl, Marta Cremonesi, Giovanni Paganelli
Summary: Radioimmunotherapy (RIT) is a safe and effective treatment for non-Hodgkin lymphomas. Two monoclonal antibodies targeting CD20 have been approved by the FDA for the treatment of relapsing/refractory NHLs. RIT may be the most effective and least toxic anticancer agent in NHLs. However, its clinical use is still debated.
SEMINARS IN NUCLEAR MEDICINE
(2022)
Review
Oncology
Rada Amin, Mounia S. Braza
Summary: This review provides a detailed description of the impact of epigenomic alterations on the immune microenvironment in follicular lymphoma (FL) and discusses the latest progress in targeting epigenetic pathways to inhibit the FL microenvironment. The article highlights unexplored research areas and key questions that need to be addressed.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
(2022)
Article
Hematology
Victor A. Chow, Ryan D. Cassaday, Theodore A. Gooley, Stephen D. Smith, Brenda M. Sandmaier, Damian J. Green, Johnnie J. Orozco, Sherilyn A. Tuazon, Manuela Matesan, Darrell R. Fisher, David G. Maloney, Oliver W. Press, Ajay K. Gopal
Summary: This study found that high-dose Y-90-ibritumomab tiuxetan, fludarabine, and low-dose total body irradiation followed by HLA-matched allo-HCT is a safe and effective treatment for aggressive BCL, achieving deeper remission and survival rates exceeding the preset endpoint.
Review
Oncology
Celia Dobano-Lopez, Ferran Araujo-Ayala, Neus Serrat, Juan G. Valero, Patricia Perez-Galan
Summary: This review discusses the interaction between tumor cells and the microenvironment in the development of follicular lymphoma, as well as the impact of genetic mutations on the tumor microenvironment and potential therapeutic approaches. Research has uncovered specific cellular phenotypes in the FL microenvironment, with recurring mutations such as KMT2D, CREBBP, EZH2, and TNFRSF14 playing a significant role in modulating this interaction. Novel therapies targeting the FL microenvironment aim to disrupt the contact network, weaken tumor cell support, and enhance the host's immune response against the tumor.
Review
Biochemistry & Molecular Biology
Tianyuan Xu, Zhong Zheng, Weili Zhao
Summary: Follicular lymphoma (FL) is a heterogeneous lymphoma originating from germinal center B cells. Multi-omics analysis has revealed abnormalities in FL cells and tumor microenvironment, providing insights into the mechanisms of FL progression and potential therapeutic options.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
(2023)
Article
Oncology
Armando Lopez-Guillermo, Miguel Angel Canales, Ivan Dlouhy, Santiago Mercadal, Javier Briones, Alejandro Martin Garcia-Sancho, Juan Manuel Sancho, Jose Maria Moraleda, Maria Jose Terol, Antonio Salar, Luis Palomera, Santiago Gardella, Isidro Jarque, Secundino Ferrer, Joan Bargay, Andres Lopez, Carlos Panizo, Anna Muntanola, Carlos Montalban, Eulogio Conde, Miguel T. Hernandez, Alfons Soler, Jose A. Garcia Marco, Guillermo Deben, Julian Marin, Jose Francisco Tomas
Summary: In this study, no significant differences were found between consolidation and maintenance in FL patients responding to R-CHOP, although consolidation therapy was associated with higher late toxicity, requiring closer monitoring.
LEUKEMIA & LYMPHOMA
(2022)
Review
Radiology, Nuclear Medicine & Medical Imaging
Francesco Cicone, Giulia Santo, Caroline Bodet-Milin, Giuseppe Lucio Cascini, Francoise Kraeber-Bodere, Caroline Stokke, Arne Kolstad
Summary: Systemic radioimmunotherapy (RIT) is considered the most effective and least toxic treatment for non-Hodgkin lymphoma (NHL). Despite a decrease in the number of patients referred for RIT in western countries, RIT has continued to evolve with the identification of new therapeutic targets, production of new vector molecules, and availability of innovative radionuclides.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Article
Oncology
Vittorio Stefoni, Lisa Argnani, Matteo Carella, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Alessandro Broccoli, Cinzia Pellegrini, Laura Nanni, Paolo Elia Coppola, Pier Luigi Zinzani
Summary: Achieving minimal disease status before autologous stem cell transplantation (ASCT) is crucial for Hodgkin lymphoma (HL) patients. This retrospective study evaluated the effectiveness and safety of the BEGEV regimen as a first salvage treatment prior to ASCT in HL patients. The results showed that the BEGEV regimen was able to induce complete response in a significant number of patients with limited toxicity, and did not impair peripheral blood stem cell mobilization.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Alessandro Broccoli, Lisa Argnani, Paolo Elia Coppola, Marianna Gentilini, Gianmarco Bagnato, Ginevra Lolli, Matteo Carella, Laura Nanni, Alice Morigi, Beatrice Casadei, Cinzia Pellegrini, Vittorio Stefoni, Pier Luigi Zinzani
Summary: After treatment with brentuximab vedotin, a proportion of patients who failed autologous stem cell transplantation for Hodgkin lymphoma can achieve and maintain long-term complete remission, indicating cure. The role of allogeneic transplantation in these patients is still being debated.
Review
Hematology
Georg Hess, Martin Dreyling, Lucie Oberic, Eva Gine, Pier Luigi Zinzani, Kim Linton, Adam Vilmar, Mats Jerkeman, Jenny M. H. Chen, Anke Ohler, Stephan Stilgenbauer, Catherine Thieblemont, Jonathan Lambert, Vittorio Ruggero Zilioli, Juan-Manuel Sancho, Ana Jimenez Ubieto, Luca Fischer, Toby A. Eyre, Sam Keeping, Julie E. Park, James J. Wu, Rubina Siddiqi, John Reitan, Sally Wade, Gilles Salles
Summary: Relapsed Mantle cell lymphoma (MCL) has a poor prognosis and there is no standard treatment. This study examined the outcomes of salvage therapy in MCL patients who failed Bruton tyrosine kinase inhibitor (BTKi) therapy, showing shorter overall survival in this group compared to those who received post-BTKi therapy.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Oncology
Carmelo Carlo-Stella, Pier Luigi Zinzani, Anna Sureda, Luis Araujo, Olivier Casasnovas, Cecilia Carpio, Su-Peng Yeh, Krimo Bouabdallah, Guillaume Cartron, Won Seog Kim, Raul Cordoba, Youngil Koh, Alessandro Re, Daniela Alves, Martine Chamuleau, Steven Le Gouill, Armando Lopez-Guillermo, Ilidia Moreira, Marjolein W. M. van der Poel, Giovanni Abbadessa, Robin Meng, Ran Ji, Lucie Lepine, Rao Saleem, Vincent Ribrag
Summary: This study evaluated the safety, efficacy, and pharmacokinetics of a combination treatment of Cemi (anti-PD-1 receptor antibody) and Isa (anti-CD38 antibody) in patients with relapsed or refractory lymphoma. The results showed that the combination treatment had manageable safety and modest clinical efficacy in patients with cHL, DLBCL, and PTCL.
HEMATOLOGICAL ONCOLOGY
(2023)
Article
Oncology
John Kuruvilla, Philippe Armand, Mehdi Hamadani, Justin Kline, Craig H. Moskowitz, David Avigan, Joshua D. Brody, Vincent Ribrag, Alex F. Herrera, Franck Morschhauser, Abraham Kanate, Pier Luigi Zinzani, Jacob Bitran, Herve Ghesquieres, Stephen J. Schuster, Mohammed Farooqui, Patricia Marinello, Nancy L. Bartlett
Summary: The study evaluated the safety and efficacy of pembrolizumab in patients with relapsed or refractory NHL. The results showed that pembrolizumab had good efficacy in PMBCL in patients who were ineligible or failed hematopoietic cell transplantation, but its efficacy in other NHL subtypes was uncertain. Hematologic toxicities were common treatment-related adverse events.
LEUKEMIA & LYMPHOMA
(2023)
Review
Radiology, Nuclear Medicine & Medical Imaging
Lucia Zanoni, Davide Bezzi, Cristina Nanni, Andrea Paccagnella, Arianna Farina, Alessandro Broccoli, Beatrice Casadei, Pier Luigi Zinzani, Stefano Fanti
Summary: Non-Hodgkin lymphomas encompass a diverse group of lymphoproliferative disorders with varying clinical courses. 18F-FDG-PET/CT is the current gold standard diagnostic imaging for staging, restaging, and treatment evaluation in lymphomas with high glucose avidity. PET-based response criteria are now uniformly applied in FDG-avid lymphomas, and this article provides updates on the management of diffuse large B-cell lymphoma, follicular lymphoma, and other histotypes, as well as the use of PET-derived factors for patient stratification and prognostication, and emerging radiomics research. Published in Semin Nucl Med 53:320-351 (c) 2022 by Elsevier Inc.
SEMINARS IN NUCLEAR MEDICINE
(2023)
Article
Immunology
Serena De Matteis, Michele Dicataldo, Beatrice Casadei, Gianluca Storci, Noemi Laprovitera, Mario Arpinati, Enrico Maffini, Pietro Cortelli, Maria Guarino, Francesca Vaglio, Maria Naddeo, Barbara Sinigaglia, Luca Zazzeroni, Serafina Guadagnuolo, Enrica Tomassini, Salvatore Nicola Bertuccio, Daria Messelodi, Manuela Ferracin, Massimiliano Bonafe, Pier Luigi Zinzani, Francesca Bonifazi
Summary: Inflammatory complications, such as ICANS, can affect the infusion of CAR T cells in patients with R/R-BCL. This study found that a lower percentage of CD3(+)CD8(+) lymphocytes and higher levels of CRP were associated with ICANS. Additionally, ICANS patients had an increase in senescent CD8(+) T cells and M-MDSC, as well as elevated levels of EVs carrying myeloid markers and cytokines.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Hematology
Philippe Armand, Pier Luigi Zinzani, Hun Ju Lee, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Alex F. Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H. Moskowitz
Summary: This study demonstrates that Pembrolizumab provides durable antitumor activity in patients with relapsed or refractory classical Hodgkin lymphoma, and a second course of treatment can reinduce sustained responses after relapse from initial complete response.
Article
Hematology
Pier Luigi Zinzani, Catherine Thieblemont, Vladimir Melnichenko, Krimo Bouabdallah, Jan Walewski, Alejandro Majlis, Laura Fogliatto, A. Martin Garcia-Sancho, Beth Christian, Zafer Gulbas, Muhit Ozcan, Guilherme Fleury Perini, Herve Ghesquieres, Margaret A. Shipp, Seth Thompson, Samhita Chakraborty, Patricia Marinello, Philippe Armand
Summary: Previous analysis of the KEYNOTE-170 study showed that pembrolizumab was effective and safe in treating relapsed/refractory PMBCL patients who had disease progression after autologous stem cell transplantation or were ineligible for the procedure. The final analysis revealed that after 4 years of follow-up, pembrolizumab still demonstrated durable responses and promising trends for long-term survival, with acceptable safety.
Article
Oncology
Marianna Gentilini, Beatrice Casadei, Alice Morigi, Ginevra Lolli, Marco Ferrari, Matteo Carella, Lisa Argnani, Pier Luigi Zinzani
Summary: Endobronchial localization of Hodgkin lymphoma is rare and there have been few reports in the literature since the 1900s. This study presents the first case of a relapsed/refractory Hodgkin lymphoma patient with a critical vegetative mass at the level of the trachea, successfully treated with pembrolizumab.
Article
Pharmacology & Pharmacy
Chun Liu, Pier Giorgio Cojutti, Maddalena Giannella, Marcello Roberto, Beatrice Casadei, Gianluca Cristiano, Cristina Papayannidis, Nicola Vianelli, Pier Luigi Zinzani, Pierluigi Viale, Francesca Bonifazi, Federico Pea
Summary: CAR T-cell therapy may cause cytokine release syndrome (CRS) and acute kidney injury, potentially affecting the pharmacokinetics of beta-lactam drugs. This study found that the clearance of meropenem and piperacillin did not need to be reduced in CAR T-cell patients experiencing CRS.
Article
Hematology
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M. Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A. Johnson, Neha Mehta-Shah, Julie Lisano, Rachael Wen, Alev Akyol, Alison J. Moskowitz
Summary: The combination therapy of nivolumab and brentuximab vedotin showed long-term efficacy in patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL), suggesting potential clinical applications.
Article
Hematology
Livio Pagano, Pier Luigi Zinzani, Stefano Pileri, Pietro Quaglino, Branko Cuglievan, Emilio Berti, Naveen Pemmaraju, Francesco Onida, Rein Willemze, Alberto Orfao, Giovanni Barosi
Summary: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with recurrent skin nodules, aggressive clinical course, and poor prognosis. Due to its rarity, there is limited research, lack of controlled clinical trials, and absence of evidence-based guidelines for its management. This review presents recommendations and proposals by a panel of experts to address the unmet clinical needs in the management of BPDCN. The hope is that this comprehensive overview will improve the practice of BPDCN and guide future studies in the field.
Article
Hematology
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela Mckay, Sophie Leitch, Morton Coleman, Pier Luigi Zinzani, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Peter Browett, Xiaoyan Ke, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Summary: The final analysis of MAGNOLIA demonstrated that zanubrutinib provided sustained clinical responses and favorable safety/tolerability in patients with relapsed/refractory marginal zone lymphoma.
Article
Hematology
Stephen M. Ansell, Paul J. Brockelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trneny, Mariano Provencio, Ulrich Jaeger, Wolfgang Willenbacher, Rachael Wen, Alev Akyol, Joanna Mikita-Geoffroy, Margaret A. Shipp, Andreas Engert, Philippe Armand
Summary: This study demonstrates that nivolumab provides frequent and durable responses in patients with relapsed/refractory classical Hodgkin lymphoma after autologous hematopoietic cell transplantation failure. Results suggest that treatment can be discontinued after persistent complete remission and resumed upon disease progression.
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)
